Halozyme Therapeutics (NASDAQ:HALO) Updates FY 2025 Earnings Guidance

Halozyme Therapeutics (NASDAQ:HALO) issued an update on its FY 2025 earnings guidance on Thursday morning. The company provided earnings per share (EPS) guidance of 4.950-5.350 for the period, compared to the consensus estimate of 5.050. The company issued revenue guidance of $1.2 billion-$1.2 billion, compared to the consensus revenue estimate of $1.2 billion.

Halozyme Therapeutics Trading Down 0.1 %

NASDAQ:HALO opened at $57.92 on Thursday. The company has a market capitalization of $7.13 billion, a PE ratio of 16.89, a price-to-earnings-growth ratio of 0.42 and a beta of 1.25. The company has a quick ratio of 9.15, a current ratio of 7.80 and a debt-to-equity ratio of 4.14. Halozyme Therapeutics has a 52-week low of $37.73 and a 52-week high of $65.53. The stock has a fifty day simple moving average of $54.08 and a 200-day simple moving average of $54.71.

Halozyme Therapeutics (NASDAQ:HALO) last posted its quarterly earnings results on Tuesday, February 18th. The biopharmaceutical company reported $1.19 EPS for the quarter, beating the consensus estimate of $1.17 by $0.02. Halozyme Therapeutics had a return on equity of 157.78% and a net margin of 43.74%. The company had revenue of $298.01 million during the quarter, compared to analysts’ expectations of $285.74 million. On average, equities research analysts expect that Halozyme Therapeutics will post 4.73 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on the company. Piper Sandler upped their price target on Halozyme Therapeutics from $52.00 to $53.00 and gave the company a “neutral” rating in a research report on Friday, January 10th. HC Wainwright increased their price target on Halozyme Therapeutics from $70.00 to $72.00 and gave the stock a “buy” rating in a research note on Wednesday, February 19th. Benchmark reaffirmed a “buy” rating and set a $75.00 target price on shares of Halozyme Therapeutics in a research note on Thursday, February 20th. JMP Securities upped their target price on Halozyme Therapeutics from $72.00 to $73.00 and gave the company a “market outperform” rating in a report on Friday, November 1st. Finally, Wells Fargo & Company reduced their price objective on Halozyme Therapeutics from $62.00 to $57.00 and set an “equal weight” rating for the company in a research note on Monday, January 13th. Four equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $62.78.

Insiders Place Their Bets

In other news, Director Jeffrey William Henderson sold 10,000 shares of the business’s stock in a transaction that occurred on Monday, January 6th. The stock was sold at an average price of $50.01, for a total value of $500,100.00. Following the transaction, the director now owns 43,611 shares in the company, valued at $2,180,986.11. The trade was a 18.65 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 2.40% of the company’s stock.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.